Outcome of Board Meeting held on August 07, 2026

(Entero Ref: 30/SE/LC/2026-27 Date: August 7, 2026 Scrip Code BSE: 544122 NSE: ENTERO ISIN: INE010601016 Head, Listing Compliance Department Head, Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Dalal Street, Exchange Plaza, Plot No. C/1. G Block, Mumbai - 400001 Bandra -Kurla Complex, Bandra (East), Mumbai- 400051 Dear Sir/Madam, Subject: Outcome of Board Meeting held on August 7, 2026 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we hereby inform you that the Board of Directors of the Company, at its meeting held today, inter alia, considered and approved the following: a) Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026, along with Limited Review Reports with unmodified opinion thereon, issued by the Statutory Auditors of the Company, are enclosed as Annexure, pursuant to Regulation 33 of SEBI LODR. b) Reconstituted the following committees of the Board of Directors, with effect from August 25, 2026, consequent upon the completion of the tenure of Rajesh Shashikant Dalal (DIN: 03504969) as a Non-Executive Independent Director Director on August 24, 2026: Audit Committee: Sr. No. Name of Directors Designation Chairperson/ Member 1 Sandhya Gadkari Sharma Non- Executive Independent Director Chairperson 2 Sujesh Vasudevan Non-Executive Independent Director Member 3 Prabhat Agrawal Managing Director & CEO Member Nomination and Remuneration Committee: Sr. No. Name of Directors Designation Chairperson/ Member 1 Sandhya Gadkari Sharma Non- Executive Independent Director Chairperson 2 Sujesh Vasudevan Non-Executive Independent Director Member 3 Arun Sadhanandham Non-Executive Nominee Director Member Stakeholders Relationship Committee: Sr. No. Name of Directors Designation Chairperson/ Member 1 Sujesh Vasudevan Non- Executive Independent Director Chairperson 2 Arun Sadhanandham Non-Executive Nominee Director Member 3 Prem Sethi Whole Time Director & COO Member Registered office: Plot No. 1-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com Corporate office: Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra. Tel.: 022-26529100 / 69019100, CIN: L74999HR2018PLC072204 (Entero Further to our intimation letter dated June 23, 2026, bearing reference no. 15/SE/LC/2026-27 and pursuant to the Company's Code of Fair Disclosure of Unpublished Price Sensitive Information, framed under the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company, shall open after expiry of 48 hours from disclosure the financial results. The above intimation is also being made available on the website of the Company at www.enterohealthcare.com The Board Meeting commenced at 01:30 P.M. (IST) and concluded at 03:45 P.M. (IST). You are requested to take the same on record. Yours faithfully, For Entero Healthcare Solutions Limited Sanu Kapoor Vice President- Group General Counsel, Company Secretary & Compliance Officer Registered office: Plot No. 1-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com Corporate office: Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra. Tel.: 022-26529100 / 69019100, CIN: L74999HR2018PLC072204 Entero Entero Healthcare Solutions Limited Registered Office: Plot No. -35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003 Corporate Office: Entero House, Crystal Plaza -158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra CIN:L 74999HR2018PLC072204 Tel. No.: 022-26529100 Email: info@enterohealthcare.com Website: www.enterohealthcare.com Statement of unaudited Standalone Financial Results for the quarter ended 30 June 2026 (Rs. in Millions, except per equity share data) Quarter ended Year ended Sr. 31 March 2026 Particulars 30 June 2026 30 June 2025 31 March 2026 No. (Audited) (Unaudited) (Unaudited) (Audited) (refer note 6) 1 Income a) Revenue from operations 832.66 789.32 793.52 3,482.41 b) Other income 231.45 399.56 262.88 1,137 23 Total Income 1,064.11 1,188.88 1,056.40 4,619.64 2 Expenses a) Purchase of Stock-in-trade 568.13 495.29 959.13 2,780.65 b) Changes in inventories of Stock-in-trade 161.05 253.16 (258.23) 356.41 c) Employee benefits expense 122.94 144.33 139.78 578.72 d) Finance costs 57 42 26.04 5.94 46.08 e) Depreciation and amortisation expense 3107 27.78 28 23 117.22 f) Other expenses 77.45 121.90 89.91 393.73 Total Expenses 1,018.06 1,068.50 964.76 4,272.81 3 Profit before exceptional items and tax(1)-(2) 46.05 120.38 91.64 346.83 4 Exceptional ltems . 44.97 5 Profit before tax (3)-(4) 46.05 120.38 91.64 301.86 6 Tax expenses Current tax (including tax expense of earlier year) 2.20 1.15 89.06 Deferred tax charge/(credit) 9.28 (14.93) 22.07 (55.95) Total tax expenses 11.48 (13.78) 22.07 33.11 7 Profit for the period/year (5) -(6) 34.57 134.16 69.57 268.75 8 Other comprehensive income ltems that will not be reclassified subsequently to profit and loss Remeasurement gain/ (loss) on defined benefit plan (0.94) (2.86) 0.39 (3.75) Income tax effect on above 0.24 0.72 (0.10) 0.94 Total other comprehensive income (0.70) (2.14) 0.29 (2.81) 9 Total comprehensive income (7) + (8) 33.87 132.02 69.86 265.94 10 Paid-up equity share capital (face value - Rs. 10 per share) 435.23 435.11 435.09 435.11 11 Other equity 16,395.25 12 Earnings per share (Face value of s.10 each) basic-(Rs.) 0.79 3.08 1.60 6.18 Earnings per share (Face value of Rs.10 each) diluted - (Rs.) 0.79 3.08 1.60 6.17 (not annualised for the quarters) See accompanying notes to the unaudited standalone financial results Entero Entero Healthcare Solutions Limited Registered Office: Plot No. -35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003 Corporate Office: Entero House, Crystal Plaza - 158,C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra CIN :L74999HR2018PLC072204 Tel. No.: 022-26529100 Email: info@enterohealthcare.com Website: www.enterohealthcare.com NOTES: The unaudited standalone financial results are prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', the provisions of the Companies Act, 2013 (the Act), and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05 July 2016, as amended. In terms of Regulation 33 of the SEBl (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, the above unaudited standalone financial results of Entero Healthcare Solutions Limited ("the Company") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors, at their respective meetings held on 7 August 2026. The statutory auditors have expressed an unmodified conclusion on these unaudited standalone financial results. 2 The Company operates only in one business segment i.e. trading of pharmaceutical and surgical products and hence, the Company has only one reportable segment as per Ind AS 108 Operating Segments". 3 Duringthe quarter ended 30 June 2026, the Company_has subscribed to the Optionally_Convertible Debenture ('OCD')issued byits subsidiaries, detailed as tallows: Name of the entity Umit number Date at issuance Issue pnce Saurashtra Medisntutone Private Limited 36,250 9 May 2026 3,300 Sri Parshva Pharma Distributors Private Limited 38,000 17 April 2026 8,400 S.S. Pharma Traders Private limited 4,000 22 May 2026 55,000 Avenues Pharma Distributors Private Limited 62,500 18 April 2026 5,600 4 During the quarter ended 30 June 2026, the Company has allotted 12,135 equity shares of Rs.10 each at a premium of [Showing first 8,000 characters — download PDF for full document]